Oruka Therapeutics, Inc. — Net Income by Fiscal Year
23 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/3dadccc4-278d-484c-adf2-c282b5862150/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-105.4M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-026929 |
| FY 2024 | $-83.7M | 2024-01-01 – 2024-12-31 | evidence 0001213900-26-045159 |
| FY 2023 | $-5.3M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-009809 |
| FY 2022 | $-9.9M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-004379 |
| FY 2021 | $-19.3M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-010075 |
| FY 2020 | $-9.7M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-014148 |
| FY 2019 | $-5.5M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-005032 |
| FY 2018 | $-7.9M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-004882 |
| FY 2017 | $-18.5M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-006566 |
| FY 2016 | $-16.4M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-004897 |
| FY 2015 | $-11.4M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-014989 |
| FY 2014 | $-9.7M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-001840 |
| FY 2013 | $-77.3M | 2001-12-18 – 2014-03-31 | evidence 0001564590-14-002121 |
| FY 2012 | $-69.1M | 2001-12-17 – 2013-03-31 | evidence 0001564590-13-000015 |
| FY 2011 | $-65.1M | 2001-12-17 – 2012-03-31 | evidence 0001193125-12-231528 |
| FY 2010 | $-8.4M | 2010-01-01 – 2010-12-31 | evidence 0001193125-11-223373 |
| FY 2009 | $-9.1M | 2009-01-01 – 2009-12-31 | evidence 0001193125-11-223373 |
| FY 2008 | $-19.4M | 2008-01-01 – 2008-12-31 | evidence 0001193125-11-223373 |
| FY 2007 | $-14.0M | 2007-01-01 – 2007-12-31 | evidence 0001193125-11-223373 |
| FY 2006 | $-5.2M | 2006-01-01 – 2006-12-31 | evidence 0001193125-11-223373 |
| FY 2005 | $-1.5M | 2005-01-01 – 2005-12-31 | evidence 0001193125-11-223373 |
| FY 2004 | $-511.0k | 2004-01-01 – 2004-12-31 | evidence 0001193125-11-223373 |
| FY 2003 | $-116.0k | 2001-12-17 – 2003-12-31 | evidence 0001193125-12-231528 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Oruka Therapeutics, Inc. — all facts · Revenue · Operating Income